DD Support Board and Research Team

[Zorax]

https://sites.google.com/site/southerncherokeenationredfire/important-notices

Is this anything like that crazy lady and the county of machalvelich or whatever it is called where she was her own country?

[Koog]

From the official Cherokee web site in 2000:

http://www.cherokee.org/News/Stories/22692

So-called Southern Cherokees Claims False

TAHLEQUAH, Okla.-Let the buyer beware. A group calling themselves the Southern Cherokee Nation claims to be a sovereign nation and has announced plans to open up casino gambling on boats on the Arkansas River. This group is not a federally recognized tribe, but rather one of more than 200 groups across the United States that claim to be Cherokee. The federal government recognizes just three Cherokee groups as tribes: the Cherokee Nation, the Eastern Band of Cherokee Indians, and the United Keetowah Band of Cherokees.

Of the remaining groups, many are just clubs whose members may or may not belong to a Cherokee tribe, but enjoy learning about the history, language and traditions of the Cherokees.

However, some groups, such as the Southern Cherokees, are not as innocuous. They are claiming land, treaty rights, and sovereign status. Information on the group's own web site states that they are a "Branch of the United Deist Association, who afforded the group…. tax exempt status in both North and South Carolina."

"It's hard to claim to be a sovereign nation with land in Oklahoma and have your only recognition be on the East Coast," said Richard Allen, the senior research analyst for the Cherokee Nation. "I don't know who these guys are. Their phone numbers are in Missouri. People know how to find the true Cherokee Nation. We've been in Tahlequah for about 160 years."

In the past, government agencies have exposed fraudulent organizations purporting to be Cherokee. One group conned investors with a scheme to create it's own nation on an island in the Rio Grande. Other scammers have claimed to be a Cherokee tribe and solicited donations, or issued coins claiming to be the official currency of the Cherokee Nation.

"These people have no legitimate claims," said Allen. "This area is the jurisdiction of the Cherokee Nation and no other sovereign tribal entity. We see these get rich quick schemes all the time. The problem is that these people may be taking the goodwill and reputation that Cherokees have established over centuries and using it to mislead governments and individual citizens," said Allen.

When seeking authentic information about tribal culture, history, traditions, genealogy and government, the public should carefully look into claims made by groups that are not recognized by the federal government, especially those that claim to represent a tribe or the Cherokee Nation. For further information with regard to dispelling myths and exposing frauds, call the Cherokee Nation or the Bureau of Indian Affairs for a list of legitimate nations, tribes and bands.

[janice shell]

Evidently there are some experts who have their doubts about Soon Shiong, and suspect he's largely just a huckster. As you say, that IPO wasn't particularly successful.

[SamLBInj]

There were these Two Guys who tried to Change that saying and took there Horse down to the Creek.
The One guy said
"You hold his Head in the Water and ill Suck on his Ass and well Make him Drink"
After a Few Minutes of this the Guy says,
"Pull his head up a Little, All I'm Getting is Mud"

[stockmasterflash]

In response to your post on the KEYO board

since likely there are more of us here familiar with Dr PSS and his scams than are left there. Remember his IPO NANT NK? That one didn't last long

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=135032120

Im not PSS fan. I believe he is a yet to be exposed fraudster

So adept with the baffling them with bullshit technique that no one can untangle the web of deceipt. I rememeber the 60 minutes piece where he had an entire blackboard filled with a single mathematical equation and the interviewer guched "and you understand what that all means" or something equally dumb.

That sayd, Boyden Gray is a heavy hitter. He's not an idiot. The company/drug likely was/is worthless and he saved her ass.

My bet is PSS found the kernel of truth and is promoting the crap out of it that will be his new cancer kiler stock sale theme. Not that the treatment will be of any value, but that there will be a world class pump coming out of it.

The suit, inadvertantly may be the event that exposes it (not us)

[namtae]

A question may be when and under what conditions were the shares issued to the clinical research firm.

For ex, a cash compensation agreement may have been in place. Then subsequent to the performance of services, the company is unable to make full payment in cash of its outstanding balance and negotiates a settlement in capital shares.

If the deal was for shares in the first place, it would seem to be a conflict of interest, depending on what the services were. Recruitment or study design may be less conflicting than say lead investigator

[loanranger]

Thanks, but the issue wasn't related to "determining the appropriate accounting answer for general situations"...it was generally about the propriety of issuing shares to a party who might be in a position to color some clinical trial results in order to benefit from the effect that could have on the price of shares or options that they received as compensation.

[scion]

Life Sciences
Accounting and Financial Reporting Update —
Interpretive Guidance on Research and Development
March 2017

https://www2.deloitte.com/content/dam/Deloitte/us/Documents/audit/us-audit-interpretive-guidance-on-research-and-development.pdf

US GAAP - Issues and solutions for the pharmaceutical and life sciences industries 2017 edition

The solutions presented in this publication are meant to provide a framework for determining the appropriate accounting answer for general situations.

Examples touch upon many different business practices, ranging from:
* Research and development,
* Intellectual property,
* Manufacturing and supply chain,
* Sales and marketing,
* Healthcare reform,
* Revenue recognition,
* Business combinations,
and more.

The contents of this publication are based on guidance that is effective or could be early adopted as of January 1, 2017, including ASC 606. In other solutions contained in the publication, the accounting guidance may be superseded as new guidance and interpretations emerge.

https://www.pwc.com/gx/en/pharma-life-sciences/pdf/med-tech-us_gaap-booklet.pdf

[stockmasterflash]

Kind of like when an auditor is paid in stock.

LOL

I've seen that one claimed before

[loanranger]

Auditors have hard and fast rules about such things, but it seems despite the obvious red flag that they don't exist for those responsible for the conduct of a Clinical Trials. There may be some kind of Code of Conduct somewhere and maybe someone can tell us about that.

Pfizer makes their position on the issue clear:
"Compensation must not be tied to the outcome of studies or include:
Pfizer stock or stock options....."

https://www.pfizer.com/research/research_clinical_trials/compensation_investigators


Even if it had nothing to do with a related party your statement in red should cause some concern.
("We have engaged clinical research firms and certain of the costs incurred have been paid or will be paid through the issuance of capital stock.")

[dabullishbear]

Oncolix is currently recruiting patients for the continuation of their Phase I. The issue with Oncolix has not been a shortage of patients, it has been a shortage of their drug, Prolanta.

They had enough patients ready to go for Phase I back in 2016, but were only able to bring 3 of those patients to completion. The reason they had to stop was due to the shortage of Prolanta as mentioned above. This information can be verified by calling Lisa Johnson, which I've done, who is listed on the the trial page information that you copied and pasted.

Why was there a shortage of the drug? One can only assume they had their financing sources fall by the wayside. Now that Oncolix has gone public they can fund their operation via the sale of securities.

As the company has stated and Lisa Johnson has verified, they did start phase I in 2016 and were able to compete 3 patients in that initial run. I emailed the CEO, Michael Redman, and asked him why the trial page had been updated in April 2017, but still remained in a recruiting status, and this was his response:

"Normally you do not update the site until you have audited data. Much of the biomarker work will be performed once we have dosed all the patients. Remember, the primary endpoint for a Phase 1 study is safety but it is always good to observe evidence of efficacy. So far, no adverse events due to the drug have been reported."

[TenKay]

BVTK 8K. Alliance with David Mersky’s SNNC.

https://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=12411441

[janice shell]

Well, hey. How can pixie dust hurt?

[Diogenes of Sinope]

I think this is a fair representation of the Pinkyland CEO’s Pixie Dust filled book of how to compose PR’s;

[Zorax]

I have noticed in some other questionable penny drug enterprises that the 'recruiting' stage is somewhat like the 'waiting for funding stage' with other market sector, but both have no problem selling stock in the interim. Like 10 year start up stage companies.

[cayman_west]

You nailed it

[Zorax]

Regarding links, Id suggest doing some searches of cancer trials where the indication is usually diagnosed at late stage, such as ovarian cancer. Im not here to convince you of anything, responding to your criticism

There is no criticism suggested, just asking for a link to substantiate what appears to be a slanted opinion, plus this isn't the stock board of question so ongoing discussion of that company itself and it's operations is not a subject of this DD board.
If I want to continue I could take it to the appropriate board.

As anyone else should as well.

[dabullishbear]

And they are probably going need another $30m-$50m to get through Phase III. I personally believe that Redman would try to position the company for a buyout or partnership with a major pharmaceutical company before then. He already had one of his companies bought out and ended up on the Nasdaq way back in the day.

I don't see how he can keep raising the money through selling stock. I think he has to partner or get bought out. The institutional investors who have 70%+ of the voting power will not let Redman dilute their millions into oblivion.

I believe they are banking on positive phase I results to get them in a position where they can pull this off.

IMO

[dabullishbear]

Hey I appreciate you looking into this. Idk how much research you've done outside of the current filings, but this isn't the first time Oncolix has raised money. When Oncolix was private, they were able to raise somewhere between $15m-$20m in venture capital. That's not $100m, but it's pretty good considering how small of a company they are.

[integral]

The carried interest debate that nobody gets, hello, P/E companies are not public, have no access to stock options. This is a mechanism to pay members to raise capital. Where does this capital end up? Investing in business, start ups, mezzanine rounds, IPOs , etc.

Increasing the tax from 23.6% to 43.3%, seriously, do people and their companies not want liquidity.

They debate this tax benefit goes to billionaires, hello, work in the real world and stop reading Google.

P/E companies are not spending the tax benefits, I have a P/E client that is trying to cut audit costs, lol. They are not spending investment and pass through cash flow, they are investing it.

People need to stop bull chitting

[integral]

My spouse was a financial officer of a bio that went through Phase III trials funded over $100 million back in the day when $100 million was quite a few bucks and before my spouse was my spouse. I cannot opine, and will defer, however, I am not convinced this is a scam.

[e-ore]

Ibrahim Almagarby and Microcap Equity Group LLC Charged by SEC

The Securities and Exchange Commission charged Ibrahim Almagarby and his company with acting as unregistered dealers in the sale of billions of shares of numerous penny stock issuers.

https://www.securitieslawyer101.com/2017/ibrahim-almagarby/

[elbiatcho1]

His fan club is not happy. Some have evidence of Ritch frontloading the scam

People should've taken heed of the Robert Buttrey (AKA Robert J Ritch, Bobby J Ritch) scam warnings a few months ago.

...I shouldn't be surprised.

[namtae]

Im not defending the company at all... Ive pointed out many, many concerns I have. However, I am interested in the science and seeing what comes of the next study, if it ever happens

The previous discussion was regarding the Phase 1 cohort and their clinical profile

[stockmasterflash]

$MNZO https://twitter.com/search?q=robertritch

His fan club is not happy. Some have evidence of Ritch frontloading the scam

[elbiatcho1]

They're still in recruiting status.

Locations
United States, South Carolina
ITOR/GHS Recruiting
Greenville, South Carolina, United States, 29605
Contact: Lisa Johnson, RN 864-455-3600 [e-mail]
Contact: Jill Cantrell, RN 8644553600 [e-mail]

Not even close to making the endpoint time.

Study Start Date: February 2016
Estimated Study Completion Date: January 2018
Estimated Primary Completion Date: December 2017 (Final data collection date for primary outcome measure)

The dosing schedule to be used in this trial is designed to evaluate, in increments, the safety and tolerability of Prolanta over this 90 day cycle. Subjects will be assessed for antibody presence throughout the study, initially on a weekly basis and then bi-weekly. Subjects will be initially dosed for 28 days followed by a safety assessment period, and then continue for an additional 56 days if no toxicities are observed.

Moot point talking about patients if the company can't find any.

[Arthur]

So if only a few of the 18-odd trial patients actually die during the drug trial, the company will tout it as a success ?

[namtae]

I dont get it... youre making my point

The patients enrolled almost always have terminal cancer for which no further potentially curative therapies are known.

It’s true that patients enroll in these studies because they have some hope that they might be helped by the drug being tested

[Arthur]

The ethics of clinical trials for terminally ill cancer patients
https://respectfulinsolence.com/2010/09/07/the-ethics-of-clinical-trials-for-termin-1/

More care has to be taken in Phase I trials. Phase I trials usually represent the first time that a drug is ever given to human beings. The patients enrolled almost always have terminal cancer for which no further potentially curative therapies are known. It has to be remembered that the purpose of a phase I trial is not to determine if a drug is effective against cancer, but rather to evaluate its safety, determine the maximal tolerated dose, and measure toxicity. It’s nice if tumor shrinkage is observed, but not essential for the drug to be taken to the next stage, phase II trials. It’s true that patients enroll in these studies because they have some hope that they might be helped by the drug being tested. However, IRBs are very insistent that it must be emphasized to patients enrolling in phase I trials that they are unlikely to benefit from the new drug.

[stockmasterflash]

$MNZO Robert Ritch deleted his twitter page

I suspected as much. Still remains in cached form (for now). Lumpy doesn't get that destroying evidence of a crime is a crime too!

[Arthur]

It's highly unethical to subject dying patients to a possibly toxic drug with the lame excuse "their lives weren't worth much anyways".

Besides, doing a Phase One study on sick people cannot possibly give you any useful indication on safe dosages and side effects: if a patient complains of, say, headaches, is it due to their illness, or is it a side effect of the drug being tested ?

The confounding factors are certain to drown the signal.

[janice shell]

Conspiracy thinking less likely with greater news media literacy, study suggests

I agree. However, you can lead a horse to water, but you can't make it drink.

[janice shell]

Hmmmm... That's kind of interesting.

[namtae]

Make some sense.

I believe is itself propaganda boilerplate to sell stock.

How is debating whether or not the company should be dosing sick patients in an initial phase 1 study, propaganda to sell stock?

Now, if youre suggesting the claim of efficacy should be taken with a grain of salt, Id agree and I addressed that here

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=136576595

Regarding links, Id suggest doing some searches of cancer trials where the indication is usually diagnosed at late stage, such as ovarian cancer. Im not here to convince you of anything, responding to your criticism

[Zorax]

Again, I'm not asking your opinion, I'm asking for 3rd party professional and scientific links to substantiate what I believe is itself propaganda boilerplate to sell stock.

[namtae]

The speculation regarding Oncolix's evidence of efficacy may be true but it hasnt been qualified or published for peer review... so its meaningless and shouldnt be considered

[namtae]

Its about as logical as it gets.

Is there any at all links to such a unrealistic statement?

In cancer, this is extremely common in Phase 1 safety/toxicity studies. Why? Because if the treatment is indeed toxic, the downside is limited. In the case of Oncolix, the patients were heavily treated previously and are now unresponsive. Their life expectancy is months.

Therefore, the risk is minimal.

Question:: Why on earth would a study treat "healthy patients", as was suggested previously, to determine just how toxic the treatment is?

Its really boiler plate

[Zorax]

In Phase I trials, you're merely looking for adverse effects and side effects.

It is also unethical to claim any results before the trial is over and all the data has been compiled.

Which is why I said that any speculation on chat boards at this phase or even before this phase is pure paid awareness campaigns when a ticker is involved. Even more so when the ticker has a dollar sign before it on Ihub.

[Zorax]

Not unusual to dose previously treated, unresponsive patients with a short life expectancy in Phase 1, which is where toxicity, safety & dosage outcomes are studied.

Wouldnt want to first test experimental treatments on newly diagnosed or treatment naive patients for fear of severe adverse reactions or risk of life

This is why the preferred patients unfortunately, are the ones with a short life expectancy

Is there any at all links to such a unrealistic statement?

[integral]

I don't know, but they are not audited. Further, why are they disseminating semi-annual financials? Are they a foreign issuer? Strange.

[berdboy]

i agree... was wondering what others thought as well...so many scammers..

[QTRADERQ]

Steve CEO of $ONCI posted the top left corner of the engagement letter to hide the 2nd paragraph which describes the "Scope of Work". That's just my observation as a retired CPA. He wants investors to believe the external auditor is conducting an audit (like he claimed in the PR) and as such will comply with GAAP and test and confirm accounts receivables, sales and sales returns; as well as, take a physical inventory. In reality, the relationship with Mazars USA LLP (if there is actually one) will be limited to a Review or Compilation engagement and A/R, Sales and Inventory numbers will be accepted "as is" by the outside accountant. Or the outside accountant will just make some minor adjustments at year-end for proper Sales and Inventory cut-offs.

Here's a list of deficiencies of the engagement letter ONCI posted on Twitter last week. Draw your own conclusions. Mine are it's fake and not an Audit engagement letter from ONCI and will be deleted from Twitter once the truth is revealed. JMO

pic.twitter.com/FLZapESHsn

— On4 Communications (@on4company) November 24, 2017

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=136501815

[scion]

U.S. regulator to allow CME, CBOE to list bitcoin futures

Michelle Price, John McCrank DECEMBER 1, 2017 / 2:58 AM / UPDATED AN HOUR AGO 4 MIN READ

WASHINGTON (Reuters) - The U.S. derivatives regulator said on Friday it would allow CME Group Inc and CBOE Global Markets Inc to list bitcoin futures, after the rival bourses showed their proposed contracts and trading arrangements met necessary requirements.
...
more
https://www.reuters.com/article/uk-markets-bitcoin/u-s-regulator-to-allow-cme-cboe-to-list-bitcoin-futures-idUSKBN1DV3J2

[boo boo]

Why do I get a 404 error on the ProShares UltraShort 20+ Year Treasury board? Ticker TBT

[berdboy]

why would a pinksheet with millions in revenue NOT REGISTER THEIR STOCK? or provide the atty letter for the AUDIT underway?

[12yearplan]

19:32

[stockmasterflash]

MNZO (formerly FOGC)

Robert Ritch? @robertritch
3h3 hours ago

After much deliberation and meeting with the SEC; I am resigning as the President of MNZO effect December 5. A interim President will take over MNZO. Simple Marketing and WS Services are being sold to me in exchange for my preferred shares.

https://twitter.com/robertritch?lang=en

[integral]

This bugs the heck out of me:

Note 6 - Related-Party Transactions

As of September 30, 2017, GHC was the largest stockholder of the Company, and GHC is an affiliate of GHS. An affiliate of GHS is the site for clinical trial activities. Accounts payable to GHC and GHS for services approximated $61,935 at September 30, 2017 and December 31, 2016.

We have engaged clinical research firms and certain of the costs incurred have been paid or will be paid through the issuance of capital stock. See Note 3.

Auditors are forbidden from taking stock as compensation for independence, clinical trial results based on stock based compensation, yikes.

For a bit, I was thinking no scam here, but this is a HUUUUUUUUUUUUGE RED FLAG.

[integral]

Item 4. Controls and Procedures.

(a) Management’s Conclusions Regarding Effectiveness of Disclosure Controls and Procedures.
The management of the Company is responsible for establishing and maintaining adequate internal control over financial reporting. The Company’s internal control over financial reporting is a process designed under the supervision of the Company’s Chief Executive/Chief Financial Officer to provide reasonable assurance regarding the reliability of financial reporting and the preparation of the Company’s financial statements for external purposes in accordance with U.S. generally accepted accounting principles.

With respect to the period ending September 30, 2017, under the supervision and with the participation of our management, we conducted an evaluation of the effectiveness of the design and operations of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) promulgated under the Securities Exchange Act of 1934.

Based upon our evaluation regarding the period ending September 30, 2017, the Company’s management, including its Principal Executive/Principal Financial Officer, has concluded that its disclosure controls and procedures were not effective due to the Company’s limited internal resources and lack of ability to have multiple levels of transaction review. Material weaknesses noted are lack of an audit committee, lack of a majority of outside directors on the board of directors, resulting in ineffective oversight in the establishment and monitoring of required internal controls and procedures; and management was dominated by two individuals during the three-month period ended September 30, 2017, without adequate compensating controls. Through the use of external consultants and the review process, management believes that the financial statements and other information presented herewith are materially correct.

The Company’s disclosure controls and procedures are designed to provide reasonable assurance of achieving their objectives. However, the Company’s management, including its Principal Executive and Principal Financial Officer, does not expect that its disclosure controls and procedures will prevent all error and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefit of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected.

Proper disclosure

[integral]

Net Operating Loss Tax Carry-Forwards

As of December 31, 2016, Oncolix/DE had net operating loss carryforwards of approximately $8.4 million and an Orphan Drug Tax Credit carryforward of approximately $0.4 million, but the utilization of such amounts has been severely limited by the merger in 2017 and other changes in ownership. The amount of such carryforwards as of September 30, 2017 has not been determined, but the utilization is also similarly limited. In addition, we have deferred the deduction of approximately $6.9 million in research and administrative costs as of December 31, 2016, and these may be deducted in future federal tax returns.

Current federal tax laws include substantial restrictions on the utilization of net operating loss and tax credits in the event of a change in the ownership, as such term is defined in the federal tax code. Even if the carryforwards are available, they may be subject to annual limitations, lack of future taxable income, or future ownership changes that could result in the expiration of the carryforwards before they are utilized. Our principal stockholder, GHC effected a reorganization that is expected result in a change in ownership that would restrict our ability to utilize our prior accumulated tax benefits, but we do not expect such reorganization to have a significant effect on our operations.

At December 31, 2016 and September 30, 2017, we recorded a 100% valuation allowance against our deferred tax assets as our management believes it is uncertain that they will be fully realized. If we determine in the future that we will be able to realize all or a portion of our net operating loss carryforwards, an adjustment to our net operating loss carryforwards would increase net income in the period in which we make such a determination.

Proper statement!